Nuvectis Pharma to Participate in the 37th Annual Roth Conference
Nuvectis Pharma (NVCT), a biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 37th Annual Roth Conference. The event will take place from March 17th-19th in Dana Point, California, where Ron Bentsur, Chairman and Chief Executive Officer, will engage in a fireside chat discussion.
The conference participation highlights Nuvectis's continued engagement with the investment community and its focus on developing innovative treatments for serious unmet medical needs in cancer therapy.
Nuvectis Pharma (NVCT), un'azienda biofarmaceutica specializzata in medicinali di precisione per l'oncologia, ha annunciato la sua partecipazione alla prossima 37ª Conferenza Annuale Roth. L'evento si svolgerà dal 17 al 19 marzo a Dana Point, California, dove Ron Bentsur, Presidente e Amministratore Delegato, parteciperà a una discussione informale.
La partecipazione alla conferenza sottolinea l'impegno continuo di Nuvectis con la comunità degli investitori e il suo focus nello sviluppare trattamenti innovativi per gravi necessità mediche insoddisfatte nella terapia del cancro.
Nuvectis Pharma (NVCT), una compañía biofarmacéutica especializada en medicamentos de precisión para oncología, ha anunciado su participación en la próxima 37ª Conferencia Anual Roth. El evento se llevará a cabo del 17 al 19 de marzo en Dana Point, California, donde Ron Bentsur, Presidente y Director Ejecutivo, participará en una charla informal.
La participación en la conferencia resalta el compromiso continuo de Nuvectis con la comunidad inversora y su enfoque en desarrollar tratamientos innovadores para necesidades médicas graves no satisfechas en la terapia del cáncer.
누벡티스 파마 (NVCT), 정밀 의약품을 전문으로 하는 생명공학 회사가 다가오는 제37회 로스 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 3월 17일부터 19일까지 캘리포니아 다나 포인트에서 열리며, 론 벤추르 회장 겸 CEO가 대화형 세션에 참여할 예정입니다.
컨퍼런스 참여는 누벡티스가 투자 커뮤니티와 지속적으로 소통하고, 암 치료에 있어 심각한 unmet medical needs를 위한 혁신적인 치료법 개발에 집중하고 있음을 강조합니다.
Nuvectis Pharma (NVCT), une entreprise biopharmaceutique spécialisée dans les médicaments de précision pour l'oncologie, a annoncé sa participation à la prochaine 37ème Conférence Annuelle Roth. L'événement se déroulera du 17 au 19 mars à Dana Point, Californie, où Ron Bentsur, Président et Directeur Général, participera à une discussion informelle.
La participation à la conférence souligne l'engagement continu de Nuvectis envers la communauté des investisseurs et son objectif de développer des traitements innovants pour les besoins médicaux graves non satisfaits dans la thérapie du cancer.
Nuvectis Pharma (NVCT), ein biopharmazeutisches Unternehmen, das sich auf präzisionsmedizinische Behandlungen in der Onkologie spezialisiert hat, hat seine Teilnahme an der bevorstehenden 37. jährlichen Roth-Konferenz angekündigt. Die Veranstaltung findet vom 17. bis 19. März in Dana Point, Kalifornien, statt, wo Ron Bentsur, Vorsitzender und CEO, an einer informellen Diskussion teilnehmen wird.
Die Teilnahme an der Konferenz hebt das fortwährende Engagement von Nuvectis gegenüber der Investmentgemeinschaft hervor und betont den Fokus auf die Entwicklung innovativer Behandlungen für ernsthafte, nicht erfüllte medizinische Bedürfnisse in der Krebstherapie.
- None.
- None.
FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California.
| Event | 37th Annual Roth Conference |
| Date | March 17, 2025 |
| Time | 2:30 PM Pacific Time |
| Link | https://event.summitcast.com/view/YsA9Ty4sRyad4m3F6KNZ7x/PL5B4myr3WCu9J7XMPKBt7 |
About Nuvectis Pharma
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Nuvectis Pharma Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
When and where is Nuvectis Pharma (NVCT) presenting at the Roth Conference 2025?
What is the focus area of Nuvectis Pharma's (NVCT) drug development pipeline?
Who will represent Nuvectis Pharma (NVCT) at the 2025 Roth Conference?
What type of presentation will NVCT deliver at the 37th Annual Roth Conference?
